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Ablation of MCL1 expression 
by virally induced microRNA-29 
reverses chemoresistance in  
human osteosarcomas
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Osteosarcoma is a rare disease diagnosed as malignant bone tumor. It is generally refractory to 
chemotherapy, which contributes to its poor prognosis. The reversal of chemoresistance is a major 
clinical challenge to improve the prognostic outcome of osteosarcoma patients. We developed a tumor-
specific replication-competent oncolytic adenovirus, OBP-301 (telomelysin) and assessed its synergistic 
effects with chemotherapeutic agents (cisplatin and doxorubicin) using human osteosarcoma cell lines 
and a xenograft tumor model. The molecular mechanism underlying the chemosensitizing effect of 
OBP-301 was evaluated in aspects of apoptosis induction. OBP-301 inhibits anti-apoptotic myeloid cell 
leukemia 1 (MCL1) expression, which in turn leads to chemosensitization in human osteosarcoma cells. 
The siRNA-mediated knockdown of MCL1 expression sensitized human osteosarcoma cells to common 
chemotherapeutic agents. We also found that upregulation of microRNA-29 targeting MCL1 via virally 
induced transcriptional factor E2F-1 activation was critical for the enhancement of chemotherapy-
induced apoptosis in osteosarcoma cells. Telomerase-specific oncolytic adenovirus synergistically 
suppressed the viability of human osteosarcoma cells in combination with chemotherapeutic agents. 
The combination treatment also significantly inhibited tumor growth, as compared to monotherapy, 
in an osteosarcoma xenograft tumor model. Our data suggest that replicative virus-mediated tumor-
specific MCL1 ablation may be a promising strategy to attenuate chemoresistance in osteosarcoma 
patients.
Osteosarcoma is a rare disease with less than 1,000 new cases every year diagnosed as malignant primary bone 
tumors in children and adolescents in the United States1. Despite recent advances in multi-agent chemotherapy 
and aggressive surgical resection, the poor response to chemotherapy is a major critical prognostic factor in oste-
osarcoma patients2, 3. Chemotherapy-refractory osteosarcoma patients frequently show tumor recurrence, distant 
metastasis and poor prognosis. Increasing the chemotherapy dose induced short-lasting remission, but did not 
increase survival. The survival rate has remained unchanged over the past 30 years2. Therefore, the enhancement 
of chemosensitivity is a potential approach to improve the clinical outcome of osteosarcoma patients.
The molecular mechanism underlying the resistance to chemotherapy in osteosarcoma patients is poorly 
understood. One possible mechanism is the resistance to apoptosis induced by chemotherapeutic agents4,5. The 
B-cell lymphoma 2 (BCL2) family proteins are suspected to regulate apoptotic cell death caused by chemothera-
peutic agents in human osteosarcoma cells2. The anti-apoptotic BCL2 family proteins, including BCL2 6, myeloid 
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cell leukemia 1 (MCL1)7, and B-cell lymphoma-X large (BCL-XL)8, are frequently overexpressed in human sar-
coma cells. Indeed, the suppression of BCL29, MCL17, and BCL-XL8 can enhance the chemosensitivity of human 
sarcoma cells. These findings suggest that anti-apoptotic BCL2 family proteins are potential therapeutic targets to 
improve the chemoresistance in osteosarcoma patients. Hence, the development of a novel therapy that efficiently 
suppresses the expression of anti-apoptotic BCL2 family proteins is needed.
Virus infection and replication produce exogenous viral proteins, many of which manipulate the host cellular 
machinery to allow viral persistence in the life-cycle. Indeed, adenoviral E1A, a gene product in the adenoviral 
early region, exerts tumor suppressive functions, including enhancement of chemotherapy-induced apoptosis 
via stabilization of tumor suppressors such as p53 and p2110 and inhibition of cell proliferation via suppression 
of epidermal growth factor receptor (EGFR)11 and HER212. Adenoviral E1B55kDa protein also induces the pro-
teolytic degradation of the Mre11-Rad50-NBS1 (MRN) complex, leading to the profound radiosensitization of 
human cancer cells13,14. Oncolytic virotherapy is a promising antitumor strategy to induce tumor-specific cell 
death15. These findings suggest that oncolytic viruses may influence the sensitivity of human osteosarcoma cells 
to chemotherapeutic agents.
In the present study, we show that genetically engineered telomerase-specific oncolytic adenovirus OBP-
301 (telomelysin) efficiently kills human osteosarcoma cells and markedly sensitizes them to common chem-
otherapeutic agents. Notably, targeting the anti-apoptotic BCL2 family protein MCL1 via OBP-301-induced 
microRNA-29 activation is critical as the underlying mechanism of the OBP-301-mediated chemosensitizing 
effect.
Results
In vitro cytotoxic effect of chemotherapeutic agents and OBP-301 in human osteosarcoma cells. 
We have developed a telomerase-specific replication-competent oncolytic adenovirus, OBP-301 (telomelysin), 
which induces tumor-specific cell death in a variety of human cancer cells16,17. To evaluate the therapeutic poten-
tial of chemotherapeutic agents and OBP-301 in human osteosarcoma cells, we first analyzed the in vitro cytotoxic 
effect of two chemotherapeutic agents, cisplatin (CDDP) and doxorubicin (DOX), which are frequently used 
for the treatment of osteosarcoma, and OBP-301 in 4 human osteosarcoma cell lines (MNNG/HOS, SaOS-2, 
HOS, and 143B). MNNG/HOS and SaOS-2 cells were relatively less sensitive to CDDP or DOX as compared 
to HOS and 143B cells (Fig. 1a). In combination with chemotherapeutic agents at the clinically used ratio 
(CDDP:DOX = 4:1), SaOS-2 and MNNG/HOS cells were also less sensitive to combination chemotherapy than 
HOS and 143B cells. In contrast, OBP-301 suppressed the viability of SaOS-2 and HOS cells more efficiently as 
compared to MNNG/HOS and 143B cells. These results indicate that SaOS-2 and MNNG/HOS cells are relatively 
resistant to chemotherapeutic agents in human osteosarcoma cells.
Chemosensitizing effect of OBP-301 in human osteosarcoma cells. We have recently shown the 
synergistic chemosensitizing effect of OBP-301 in human epithelial malignant tumor cells18. To investigate the 
chemosensitizing effect of OBP-301 in human osteosarcoma cells, we treated human osteosarcoma cells with 
chemotherapeutic agents and OBP-301 in combination therapy to achieve a synergistic effect. The most suitable 
condition for combination therapy was treatment with the chemotherapeutic agents for 24 hours following OBP-
301 infection for 48 hours (Suppl. Fig. 1). When cells were treated with OBP-301 and chemotherapeutic agents 
(CDDP:DOX = 4:1) by the most suitable combination protocol, cell viability was decreased in a dose-dependent 
manner (Fig. 1b). The calculation of the combination index demonstrated the synergistic antitumor effect of com-
bination therapy in all 4 human osteosarcoma cell lines (Fig. 1c). In contrast, administration of chemotherapeutic 
agents did not affect the replication efficacy of OBP-301 in SAOS-2 and MNNG/HOS cells (Suppl. Fig. 2). These 
results suggest that OBP-301 is a potent chemosensitizer in human osteosarcoma cells.
Enhancement of chemotherapy-induced apoptosis and DNA damage by OBP-301. To evaluate 
the underlying mechanism in the OBP-301-mediated enhancement of chemosensitivity, we assessed whether 
OBP-301 enhances chemotherapy-mediated apoptosis induction and DNA damage. After chemotherapy-resistant 
SaOS-2 and MNNG/HOS cells were treated with chemotherapy and/or OBP-301, apoptosis induction and DNA 
damage status were assessed by western blot and flow cytometry. Western blot analysis showed that CDDP 
and DOX induced apoptosis, which was confirmed by the increased expression of cleaved poly(ADP-ribose) 
polymerase (PARP), in a dose-dependent manner (Fig. 2a). In contrast, OBP-301 slightly induced the expres-
sion of cleaved PARP in MNNG/HOS cells, but not SaOS-2 cells (Fig. 2b). When combined with chemother-
apy, OBP-301 enhanced the chemotherapy-induced cleaved PARP expression in SaOS-2 and MNNG/HOS 
cells (Fig. 2c). Compared with enhancement of cleaved PARP expression, we could not detect the expression 
of different apoptosis indicator cleaved caspase-3 (data not shown). In contrast, the expression of DNA damage 
biomarker γ -H2AX was increased in combination therapy compared to monotherapy (Fig. 2c). TUNEL assay 
demonstrated that the percentage of TUNEL-positive cells was significantly increased in combination therapy 
compared to monotherapy (Fig. 2d and Suppl. Fig. 3). Moreover, flow cytometric analysis also revealed that OBP-
301 significantly increased the percentage of the sub-G1 population, which is a fraction of apoptotic cells, in the 
chemotherapy-treated SaOS-2 and MNNG/HOS cells (Fig. 3). These results indicate that OBP-301 mediates its 
chemosensitizing effect through the enhancement of chemotherapy-induced apoptosis and DNA damage.
Downregulation of anti-apoptotic MCL1 is a critical factor in enhancing chemotherapy-induced 
apoptosis by OBP-301. Anti-apoptotic BCL2 family proteins, such as BCL2, MCL1, and BCL-XL, play 
a critical role in the resistance to chemotherapeutic agents19. To clarify the molecular mechanism underlying 
the chemosensitizing effect of OBP-301, we assessed whether OBP-301 affects the expression of anti-apoptotic 
BCL2 family proteins in chemotherapy-resistant SaOS-2 and MNNG/HOS cells. Western blot analysis showed 
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that OBP-301 dose-dependently downregulated the anti-apoptotic MCL1 protein that was highly expressed in 
SaOS-2 and MNNG/HOS cells (Fig. 4a). The expression of other BCL2 family proteins BCL2 and BCL-XL was 
also downregulated after OBP-301 infection in SaOS-2 cells, but OBP-301 slightly increased BCL2 expression and 
BCL-XL expression was very low in MNNG/HOS cells. Moreover, when combined with chemotherapy, OBP-301 
induced MCL1 suppression in consistent with enhancement of chemotherapy-induced apoptosis in SaOS-2 and 
MNNG/HOS cells (Fig. 4b). These results suggest that OBP-301 enhances chemotherapy-induced apoptosis via 
MCL1 suppression.
To confirm the role of MCL1 suppression in the OBP-301-mediated enhancement of chemotherapy-induced 
apoptosis, we further assessed the effect of MCL1 knockdown by RNA interference on the chemotherapy-induced 
apoptosis. When combined with chemotherapeutic agents, MCL1 siRNA efficiently suppressed MCL1 expres-
sion and enhanced the chemotherapy-induced apoptosis as well as OBP-301 in SaOS-2 and MNNG/HOS cells 
(Fig. 4c). These results suggest that MCL1 suppression plays a crucial role in the OBP-301-mediated enhancement 
of chemotherapy-induced apoptosis.
Figure 1. OBP-301 synergistically enhances the cytotoxic effect of chemotherapeutic agents in human 
osteosarcoma cells. (a) Four human osteosarcoma cell lines (SaOS-2, MNNG/HOS, HOS, and 143B) were 
treated with cisplatin (CDDP) or doxorubicin (DOX) at the indicated doses for 24 hours. In combined 
chemotherapy, cells were treated with CDDP and DOX at the clinically used ratio (CDDP:DOX = 4:1) for 
24 hours. Cells were infected with OBP-301 at the indicated MOIs for 3 days. Cell viability was quantified using 
the XTT assay. Cell viability was calculated relative to that of the mock-infected group, which was set at 1.0. 
Cell viability data are expressed as mean values ± SD (n = 5). (b) In combination therapy with chemotherapy 
and OBP-301, cells were infected with OBP-301 at the indicated MOIs. Two days after viral infection, cells 
were further treated with CDDP and DOX (CDDP:DOX = 4:1) for 24 hours. (c) The combination index was 
calculated with the CalcuSyn software (BioSoft, Inc.). Synergism and antagonism were defined as interaction 
indices of < 1 or > 1, respectively.
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OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 
activation. We recently revealed that OBP-30120 and tumor suppressor p53-expressing OBP-301 (OBP-702)21 
increase the expression of cellular microRNAs (miRNAs) miR-7 and miR-93/106b, respectively, via activation 
of transcription factor E2F1 in human cancer cells. miR-15, miR-16, and miR-29 suppress MCL1 expression 
in human malignant tumor cells22. Moreover, a recent report has suggested that miR-16 and miR-29 are down-
regulated and miR-15 is associated with chemosensitivity in human osteosarcoma cells23. To investigate the 
underlying mechanism of OBP-301-mediated MCL1 suppression, we determined whether OBP-301 upregulates 
MCL1-targeted miRNAs (miR-15, miR-16, miR-29) via E2F1 activation in human osteosarcoma cells. OBP-301 
dose-dependently upregulated the expression of E2F1 and MCL1-targeted miRNAs (miR-15a, miR-16, miR-29a) 
in SaOS-2 and MNNG/HOS cells (Fig. 5a,b). In contrast, when infected with E2F1-expressing Ad-E2F1 or control 
E1A-deleted adenovirus dl312, Ad-E2F1 increased E2F1 expression and inversely decreased MCL1 expression 
in SaOS-2 and MNNG/HOS cells (Fig. 5c). Moreover, Ad-E2F1 significantly increased the expression of miR-
15a, miR-16, and miR-29a in SaOS-2 cells, although MNNG/HOS cells showed increased expression of miR-15a 
and miR-16, but not miR-29a, after Ad-E2F1 infection (Fig. 5d). These results suggest that OBP-301 induces 
MCL1-targeted miRNAs via E2F1 activation in human osteosarcoma cells.
To evaluate the effect of MCL1-targeted miRNAs in the chemosensitivity of human osteosarcoma cells, we 
introduced exogenous miR-15a, miR-16, miR-29a or control miRNA into SaOS-2 and MNNG/HOS cells. Only 
miR-29a efficiently suppressed MCL1 expression in SaOS-2 and MNNG/HOS cells (Fig. 5e). Moreover, miR-29a 
Figure 2. OBP-301 enhances chemotherapy-induced apoptosis and DNA damage. Western blot analysis 
was performed under the same experimental conditions. (a) Expression of PARP and cleaved PARP (C-PARP) 
proteins in SaOS-2 and MNNG/HOS cells treated with chemotherapeutic agents (CDDP, DOX) at the indicated 
doses. (b) Expression of PARP, C-PARP and adenoviral E1A proteins in SaOS-2 and MNNG/HOS cells treated 
with OBP-301 at the indicated MOIs. (c) Expression of PARP, C-PARP, γ -H2AX, and adenoviral E1A proteins in 
SaOS-2 and MNNG/HOS cells treated with OBP-301 and chemotherapeutic agents (CDDP, DOX). β -actin was 
used as a loading control. (d) The percentage of apoptotic population was analyzed by TUNEL assay in SaOS-2 
and MNNG/HOS cells after treatment with control, CDDP, DOX, OBP-301, or the combination of OBP-301 
and chemotherapeutic agents. Cells were infected with OBP-301 at doses of 10 or 50 MOI, respectively. Two 
days after OBP-301 infection, cells were treated with cisplatin (CDDP) or doxorubicin (DOX) at 5 or 1 μ g/ml,  
respectively, for 24 hours. Data are expressed as mean values ± SD (n = 5). Statistical significance (* ) was 
defined as P < 0.05.
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enhanced the chemotherapy-induced apoptosis in SaOS-2 and MNNG/HOS cells (Fig. 5f). These results sug-
gest that OBP-301 enhances chemotherapy-induced apoptosis through miR-29-mediated MCL1 suppression in 
human osteosarcoma cells.
Suppression of MNNG/HOS tumor growth by the combined treatment of chemotherapeutic 
agents and OBP-301. Finally, to assess the in vivo antitumor effect of combination therapy with chemother-
apy and OBP-301, we used a subcutaneous MNNG/HOS xenograft tumor model because only MNNG/HOS cells 
have tumorigenic ability24. OBP-301 or PBS (mock) was injected into the tumors every week, whereas cisplatin 
and doxorubicin were intraperitoneally injected 2 days after OBP-301 injection for 3 cycles. The combination 
of chemotherapeutic agents and OBP-301 significantly suppressed tumor growth when compared to mock or 
monotherapy with chemotherapeutic agents or OBP-301 (Fig. 6a,b). On histopathological analysis, there were 
large necrotic areas with decreased Ki-67 expression in the combination therapy-treated tumors as compared 
to mock-treated, OBP-301- or chemotherapy-treated tumors (Fig. 6c). Combination therapy with OBP-301 and 
chemotherapy significantly decreased the number of Ki67-positive proliferating cells within tumor tissues com-
pared to mock or monotherapy (Fig. 6d). These results suggest that OBP-301 has the therapeutic potential to 
enhance the chemotherapy-mediated antitumor effect in human osteosarcoma tumors.
Figure 3. OBP-301-mediated enhancement of apoptosis in combination with chemotherapy. (a) The 
cell-cycle state was analyzed by flow cytometry in SaOS-2 and MNNG/HOS cells stained with propidium 
iodide after treatment with mock (control), CDDP, DOX, OBP-301, or the combination of OBP-301 and 
chemotherapeutic agents (CDDP, DOX). SaOS-2 and MNNG/HOS cells were infected with OBP-301 at doses 
of 10 or 50 MOI, respectively. Two days after OBP-301 infection, cells were treated with cisplatin (CDDP) or 
doxorubicin (DOX) at 5 or 1 μ g/ml, respectively, for 24 hours. Representative cell-cycle data are shown. (b) The 
percentage of sub-G1 population was analyzed using flow cytometry in SaOS-2 and MNNG/HOS cells after 
treatment with control, CDDP, DOX, OBP-301, or the combination of OBP-301 and chemotherapeutic agents. 
Data are expressed as mean values ± SD (n = 3). Statistical significance (* ) was defined as P < 0.05.
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Discussion
The exploration of the molecular mechanism underlying chemoresistance and the development of novel strat-
egies for enhancing chemosensitivity are pivotal approaches to improve the clinical outcome of osteosarcoma 
patients. The present study demonstrated that a tumor-specific replication-competent oncolytic adenovirus 
OBP-301 induced miR-29 upregulation via E2F1 activation, which resulted in suppression of anti-apoptotic 
BCL2 family protein MCL1 in chemotherapy-resistant human osteosarcoma cells. OBP-301 synergistically 
enhanced the chemosensitivity in human osteosarcoma cells by promoting chemotherapy-induced apoptosis 
and DNA damage. Although oncolytic adenoviruses hTERT-Ad25, SG51126, and OBP-30127–30 showed chemo-
sensitizing effects in epithelial types of malignant tumor cells, the precise molecular mechanism underlying the 
adenovirus-mediated chemosensitization remained unclear, especially in human osteosarcoma cells. Virally 
triggered MCL1 depletion may be a novel, promising strategy to overcome chemoresistance in human oste-
osarcomas. Moreover, activation of miRNA networks targeting MCL1 is essential for this clinically relevant 
chemovirotherapy.
MCL1 is overexpressed in various types of human tumor cells31; thus, MCL1 has emerged as a potential ther-
apeutic target. Some reports have suggested that MCL1 suppression by MCL1 siRNA and antisense oligonucle-
otides enhance the antitumor effects of chemotherapy in human cancers including sarcomas7, hepatocellular 
carcinomas32, pancreatic cancers33 and gastric cancers34. MCL1-targeted drugs, such as small molecule inhib-
itors, have recently been developed to improve the chemotherapy-mediated antitumor effect in human can-
cer cells19. However, MCL1 suppression also induces apoptosis in normal hematopoietic cells, such as B and T 
Figure 4. OBP-301-mediated MCL1 suppression enhances chemotherapy-induced apoptosis. Western 
blot analysis was performed under the same experimental conditions. (a) Expression of the anti-apoptotic 
BCL2 family proteins (MCL1, BCL2, BCL-XL) in SaOS-2 and MNNG/HOS cells infected with OBP-301 at 
the indicated MOIs for 72 hours. (b) Expression of PARP, cleaved PARP (C-PARP) and MCL1 proteins in 
SaOS-2 and MNNG/HOS cells treated with OBP-301 and chemotherapeutic agents (CDDP, DOX). Cells were 
infected with OBP-301 at doses of 10 or 50 MOI, respectively. Two days after OBP-301 infection, cells were 
treated with cisplatin (CDDP) or doxorubicin (DOX) at 5 or 1 μ g/ml, respectively, for 24 hours. (c) Expression 
of PARP, C-PARP and MCL1 proteins in SaOS-2 and MNNG/HOS cells treated with chemotherapeutic agents 
(CDDP, DOX) and MCL1 siRNA or control siRNA. Cells were treated with 10 nmol/L MCL1 siRNA or control 
siRNA. Two days after siRNA treatment, cells were treated with CDDP or DOX at 5 or 1 μ g/ml, respectively, for 
24 hours. β -actin was used as a loading control.
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lymphocytes35, polymorphonuclear leukocytes36, macrophages37 and hematopoietic stem cells38. To avoid the 
cytotoxicity of MCL1 suppression in normal hematopoietic cells, OBP-301-mediated tumor-specific MCL1 abla-
tion might be clinically beneficial.
Regarding the molecular mechanism underlying the oncolytic adenovirus-mediated MCL1 suppression, we 
demonstrated that OBP-301 upregulated MCL1-targeted miRNAs, such as miR-15, miR-16 and miR-29, and 
miR-29 overexpression efficiently suppressed MCL1 expression in human osteosarcoma cells. Recent reports have 
shown that MCL1 is a direct target of miR-29a, which binds to 3′ -UTR of MCL1, in human tumor cells includ-
ing SaOS-2 cells39–41. Regarding the function of miR-29 in tumor development, the miR-29 family is frequently 
downregulated in human cancers42 including osteosarcomas43, suggesting the tumor-suppressive role of the miR-29 
family. In fact, our data demonstrated that administration of a miR-29 mimic enhanced the chemotherapy-induced 
apoptosis like MCL1 siRNA. Moreover, miR-29 negatively regulates the expression of stemness-related markers, 
such as Oct3/4, Sox2 and Nanog, and subsequently suppresses the proliferation, sphere formation and chemore-
sistance of human osteosarcoma stem cells43. Therefore, OBP-301-mediated miR-29 activation may have broad 
therapeutic potential in addition to chemosensitization through MCL1 depletion. However, miR-15a, miR-16 and 
miR-29a may not be the only MCL1-targeted miRNAs because we cannot exclude the possible involvement of other 
miRNAs in regulating MCL1 expression. Comprehensive miRNA expression profiling by using either a miRNA 
microarray or a miRNA PCR array, therefore, will be necessary to clarify this issue in the future study.
Figure 5. OBP-301-mediated microRNA-29 up-regulation suppresses MCL1 expression and enhances 
chemotherapy-induced apoptosis. Western blot analysis was performed under the same experimental 
conditions. (a) Expression of E2F1 protein in SaOS-2 and MNNG/HOS cells infected with OBP-301 at the 
indicated MOIs for 72 hours. (b) Expression of miR-15a, miR-16, and miR-29a in SaOS-2 and MNNG/HOS 
cells infected with OBP-301 at the indicated MOIs for 72 hours. The values of miR-15a, miR-16, and miR-29a 
at 0 MOI were set at 1, and the relative levels of miR-15a, miR-16, miR-29a at the indicated MOIs were plotted 
as fold induction. Data are expressed as mean values ± SD (n = 3). Statistical significance (* ) was defined as 
P < 0.05. (c) Expression of E2F1 and MCL1 proteins in SaOS-2 and MNNG/HOS cells infected with Ad-E2F1 
at 100 and 1000 MOIs, respectively, for 48 hours. (d) Expression of miR-15a, miR-16, and miR-29a in SaOS-2 
and MNNG/HOS cells infected with Ad-E2F1 at 100 and 1000 MOIs, respectively, for 48 hours. (e) Expression 
of MCL1 protein in SaOS-2 and MNNG/HOS cells treated with 10 nmol/L Pre-miR-15a (15a), Pre-miR-16 
(16), Pre-miR-29a (29a), or control Pre-miRNA (C) for 72 hours. (f) Expression of PARP, C-PARP and MCL1 
proteins in SaOS-2 and MNNG/HOS cells treated with chemotherapeutic agents (CDDP, DOX) and control 
Pre-miRNA (C) or miR-29a (29a). Cells were treated with 10 nmol/L Pre-miR-29a or control Pre-miRNA. Two 
days after miRNA treatment, cells were treated with cisplatin (CDDP) or doxorubicin (DOX) at 5 or 1 μ g/ml, 
respectively, for 24 hours. β -actin was used as a loading control.
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OBP-301 treatment increased the level of miR-29a in SaOS-2 and MNNG/HOS cells. However, E1A-deficient 
Ad-E2F1-induced E2F1 overexpression was not sufficient to increase the level of miR-29a in MNNG/HOS 
cells. Previous report has suggested that adenoviral E1A accumulation is necessary to suppress MCL1 expres-
sion in adenovirus-infected cells44. Adenovirus induces E2F1 expression via E1A-mediated inactivation of 
E2F1-suppressive retinoblastoma (Rb) protein and activation of free E2F145. Since SaOS-2 cells lack Rb protein, 
but HOS cells, which are parental cells of MNNG/HOS cells, have Rb protein46, inactivation of E2F1-suppressive 
Rb protein in addition to E2F1 overexpression may be necessary to increase the level of miR-29a in MNNG/HOS 
cells.
We and our collaborators recently confirmed the antitumor effect of OBP-301 in human osteosarcoma cells as 
a monotherapy47,48. A Phase I clinical trial in the United States showed the safety and feasibility of intratumoral 
injection of OBP-301 in patients with various types of advanced solid tumors including sarcomas49. Although 
we have recently confirmed more profound antitumor effect of p53-expressing OBP-702 compared to OBP-301 
against human osteosarcoma cells21, the safety and feasibility of OBP-702 treatment in cancer patients remains 
to be elucidated. For future clinical application, we focused on the therapeutic potential of OBP-301 in a multi-
modal antitumor strategy with chemotherapy in this study. Recent evidence has shown not only the antitumor 
effect, but also the chemosensitizing effect of oncolytic adenoviruses in human cancer cells18,50. For example, 
we confirmed that OBP-301 enhances the antitumor effect of chemotherapeutic agents, such as docetaxel27, 
Figure 6. Enhancement of chemotherapy-mediated antitumor effect in combination with OBP-301 
in subcutaneous MNNG/HOS osteosarcoma xenograft model. Athymic nude mice were inoculated 
subcutaneously with MNNG/HOS-Luc cells (5 × 106 cells/site). OBP-301 (5 × 107 PFU) was injected into the 
tumor at 3, 4, and 5 weeks after tumor inoculation. Cisplatin (4 mg/kg body weight) and doxorubicin (2 mg/kg  
body weight) were intraperitoneally injected 2 days after OBP-301 injection in chemotherapy (CTX) treatment. 
(a) Representative photographs of tumor-bearing mice treated with PBS (mock), CTX, OBP-301, or OBP-
301 and CTX. (b) The luminescence in tumor tissues was analyzed using the IVIS system at 2, 3, 4, 5, and 6 
weeks after tumor inoculation. Data are expressed as mean values ± SD (n = 4). (c) histologic analysis of the 
MNNG/HOS tumors. Tumor tissues were obtained at 6 weeks after tumor inoculation. Paraffin-embedded 
sections of MNNG/HOS tumors were stained with hematoxylin and eosin solutions or anti-Ki67 antibody. 
Upper and middle images are low magnification in HE and Ki67 staining, respectively. Lower images are high 
magnification of the area outlined by a white square in Ki67 staining. Upper and middle scale bars, 200 μ m. 
Lower scale bars, 50 μ m. (d) the number of Ki67-positive cells in tumor tissue was calculated using ImageJ 
software. Statistical significance (* ) was defined as P < 0.05.
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gemcitabine28, CDDP 29,30, and paclitaxel30, in human cancer cells with telomerase activities. In this study, we 
demonstrated the potential of OBP-301 as a chemosensitizing reagent against osteosarcoma cells in in vitro and 
in vivo experiments. Chemosensitizing effect of OBP-301 was more striking in in vivo experiment compared to in 
vitro experiment. The difference between in viro and in vivo chemosensitizing effect of OBP-301 may be in part 
due to different frequency of treatment, one time (in vitro) and three times (in vivo). Short-term in vivo experi-
ment may be necessary to precisely confirm the apoptosis induction status within tumor tissues as well as in vitro 
experiment. In contrast, quiescent tumor cells are predominantly more resistant to chemotherapeutic agents than 
proliferating tumor cells within tumor tissues51. We recently reported that OBP-301 suppressed cell viability in 
chemoradiotherapy-resistant quiescent human gastric cancer stem cells through induction of cell cycle reentry52. 
In this report, OBP-301 also enhanced the chemotherapy-mediated antitumor effect against dormant human 
gastric cancer stem cell-driven tumors. OBP-301-mediated modulation of the cell cycle status may also attenuate 
the chemoresistance of dormant human osteosarcoma cells within tumor tissues.
Our findings suggest that miR-29-mediated suppression of anti-apoptotic factor MCL1 was a critical factor 
for the enhancement of chemosensitivity in human osteosarcoma cells. Thus, virus-mediated telomerase-specific 
targeting of MCL-1 expression offers a promising strategy to improve the clinical benefits of conventional chemo-
therapy in osteosarcoma patients. Further clinical studies are warranted to investigate the tolerability and efficacy 
of this multimodal combination therapy.
Materials and Methods
Cell lines. Four human osteosarcoma cell lines were used in the study. HOS and SaOS-2 cells were kindly 
provided by Dr. Satoru Kyo (Shimane University, Izumo, Japan). MNNG/HOS cells were purchased from DS 
Pharma Biomedical, and 143B cells were obtained from the American Type Culture Collection (Manassas, VA, 
USA). HOS and SaOS-2 cells were maintained in Dulbecco’s Modified Eagle’s Medium. MNNG/HOS cells were 
maintained in Eagle’s Minimum Essential Medium containing 1% nonessential amino acids. 143B cells were 
maintained in Eagle’s Minimum Essential Medium containing 0.015 mg/ml 5-bromo-2′ -deoxyuridine. MNNG/
HOS cells transfected with the firefly luciferase plasmid vector (MNNG/HOS-Luc) were maintained in medium 
containing 0.2 mg/ml Geneticin (G418; Invitrogen, Carlsbad, CA, USA). All media were supplemented with 10% 
fetal bovine serum (St. Louis, MO, USA), 100 U/ml penicillin and 100 mg/ml streptomycin. The cells were rou-
tinely maintained at 37 °C in a humidified atmosphere with 5% CO2.
Recombinant adenoviruses. Construction and characterization of the recombinant telomerase-specific 
replication-competent adenovirus vector OBP-301 (telomelysin) was previously reported16,17. 
Replication-deficient adenovirus vector expressing E2F1 (Ad-E2F1) was used to induce E2F1 expression in 
infected cells, as previously reported53. E1A-deleted adenovirus vector (dl312) was used as a control vector. OBP-
301, Ad-E2F1 and dl312 were purified by using CsCl step gradient ultracentrifugation followed by CsCl linear 
gradient ultracentrifugation. This study was approved by the Recombinant DNA Experiment Safety Committee 
and carried out in accordance with the approved protocol (Approved ID: 12015).
Cell viability assay. Cells were seeded on 96-well plates at a density of 1 × 103 cells/well 24 hours before 
administration of chemotherapeutic drugs or viral infection. In monotherapy, cells were treated with CDDP or 
DOX at a concentration of 0, 0.1, 1, 5, or 10 μ g/ml for 24 hours or infected with OBP-301 at multiplicity of infec-
tions (MOIs) of 0, 1, 5, 10, 50, or 100 plaque forming units (PFUs)/cell for 72 hours. In combined chemotherapy, 
cells were treated with chemotherapeutic agents at the ratio used clinically (CDDP:DOX = 4:1). Moreover, in 
combination therapy with chemotherapy and OBP-301, two days after viral infection with OBP-301 at the indi-
cated MOIs, cells were further treated with chemotherapy (CDDP:DOX = 4:1) for 24 hours. Cell viability was 
determined using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN, USA) according 
to the manufacturer’s protocol. The combination index was calculated with CalcuSyn software (BioSoft, Inc., 
Cambridge, UK), and the computation of the combination index was based on the methods of Chou and Talalay54.
Western blot analysis. SaOS-2 and MNNG/HOS cells seeded in a 100-mm dish at a density of 2 × 105 
cells/dish were infected with OBP-301, Ad-E2F1, or dl312 at the indicated MOIs for 72 hours. Cells were treated 
with CDDP or DOX at the indicated doses for 24 hours. Cells were transfected with 10 nM MCL1 siRNA, con-
trol siRNA, Pre-miR-15a, Pre-miR-16, Pre-miR-29a, or control Pre-miRNA (Applied Biosystems, Foster City, 
CA, USA) 48 hours before chemotherapy treatment and treated with CDDP or DOX at the indicated doses for 
24 hours. Whole cell lysates were prepared in a lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton 
X-100) containing a protease inhibitor cocktail (Complete Mini; Roche Applied Science, Mannheim, Germany). 
Proteins were electrophoresed on 8–15% sodium dodecyl sulfate polyacrylamide gels and transferred to poly-
vinylidene difluoride membranes (Hybond-P; GE Health Care, Buckinghamshire, UK). The membranes were 
blocked with Blocking-One (Nacalai Tesque, Kyoto, Japan) at room temperature for 30 minutes. The primary anti-
bodies used were: mouse anti-Ad5 E1A monoclonal antibody (mAb) (BD PharMingen, Franklin Lakes, NJ, USA); 
rabbit anti-PARP polyclonal antibody (pAb), mouse anti-γ -H2AX mAb (Upstate Biotechnology Inc., Temecula, 
CA, USA), rabbit anti-MCL1 mAb, rabbit anti-BCL-2 mAb, rabbit anti-BCL-XL mAb, and rabbit anti-E2F1 mAb 
(Cell Signaling Technology, Danvers, MA, USA); and mouse anti-β -actin mAb (Sigma-Aldrich). The secondary 
antibodies used were: horseradish peroxidase-conjugated antibodies against rabbit IgG (GE Healthcare), mouse 
IgG (GE Healthcare) or goat IgG (Chemicon International Inc., Temecula, CA, USA). Immunoreactive bands on 
the blots were visualized using enhanced chemiluminescence substrates (ECL Plus; GE Healthcare).
DNA fragmentation analysis. SaOS-2 and MNNG/HOS cells seeded in a 4 well glass plate at a density 
of 5 × 103 cells/well were treated with or without CDDP (5 μ g/ml), DOX (1 μ g/ml), and/or OBP-301 (10 and 
50 MOIs, respectively). In monotherapy, cells were treated with chemotherapy for 24 hours or infected with 
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OBP-301 for 72 hours. In combination therapy, two days after viral infection with OBP-301, cells were further 
treated with chemotherapy for 24 hours. Cells were fixed in 1% paraformaldehyde in PBS at 4 °C for 10 minutes. 
Cells were stained by nick end-labelling method to detect the fragmented DNA, and Hoechst 33342 (Thermo 
Fisher Scientific Inc., Rockford, IL, USA) to observe the nuclear morphology of the cells. Briefly, cells were incu-
bated with TdT reaction solution (400 U terminal transferase and 5 nmol Fluorescen-12-2′ -deoxy-uridine-5′ 
-triphosphate in 1.2 ml TUNEL Dilution Buffer (Roche Diagnostics, Mannheim, Germany)). The cells were then 
stained by Hoechst 33342 (20 μ M) for 5 minutes at room temperature. The photographs of immunostained sec-
tions were obtained by fluorescent microscopy. The percentage of immunoreactive cells for TUNEL was calcu-
lated in five randomly selected fields in each group.
Flow cytometric analysis. To evaluate the sub-G1 population, which is an apoptosis indicator, the cell 
cycle state was analyzed by flow cytometry, as previously reported21. SaOS-2 and MNNG/HOS cells seeded in a 
100-mm dish at a density of 1 × 106 cells/dish were treated with or without CDDP (5 μ g/ml), DOX (1 μ g/ml), and/
or OBP-301 (10 and 50 MOIs, respectively). In monotherapy, cells were treated with chemotherapy for 24 hours 
or infected with OBP-301 for 72 hours. In combination therapy, two days after viral infection with OBP-301, cells 
were further treated with chemotherapy for 24 hours. Cells were trypsinized and resuspended in original super-
natant to ensure that attached and nonattached cells were analyzed. Cells stained with propidium iodide were 
analyzed using a FACS array (BD Biosciences, Franklin Lakes, NJ, USA).
Quantitative real-time reverse transcription-PCR analysis. To evaluate the expression of miR-15a, 
miR-16, and miR-29a in tumor cells after OBP-301 infection, SaOS-2 and MNNG/HOS cells were seeded on 
6-well plates at a density of 2 × 105 cells/well and 24 hours later infected with OBP-301 at MOIs of 0, 1, 5, 10, 50, 
or 100 PFU/cell. Three days after virus infection, total RNA was extracted from cells using a miRNeasy Mini Kit 
(Qiagen, Valencia, CA, USA). After synthesis of cDNA from 10 ng of total RNA using the TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems), the expression of miR-15a, miR-16, or miR-29a was determined 
by quantitative real-time RT-PCR (qRT-PCR) using the Applied Biosystems StepOnePlusTM real-time PCR sys-
tem. The expression levels of miR-15a, miR-16, and miR-29a were defined from the threshold cycle (Ct), and 
relative expression levels were calculated using the 2−ΔΔCt method after normalization with reference to the 
expression of U6 small nuclear RNA.
In vivo MNNG/HOS xenograft tumor model. Animal experimental protocols were approved by the 
Ethics Review Committee for Animal Experimentation of Okayama University School of Medicine (No. OKU-
2011062). MNNG/HOS-Luc cells (5 × 106 cells per site) were inoculated into the flanks of 5- to 6-week-old female 
BALB/c nu/nu mice (CLEA Japan, Tokyo, Japan). Palpable tumors developed within 21 days and were permitted 
to grow to approximately 5 to 6 mm in diameter. At that stage, a 50 μ L volume of solution containing OBP-301 
(5 × 107 PFU) or PBS was injected into the tumors every week for 3 cycles. Cisplatin (4 mg/kg body weight) and 
doxorubicin (2 mg/kg body weight) were intraperitoneally injected 2 days after OBP-301 injection for 3 cycles. 
Four mice were used for each group. To monitor tumor progression, the substrate luciferin (VivoGlo Luciferin; 
Promega, Madison, WI, USA) was intraperitoneally injected at a dose of 3 mg/kg body weight. Images were col-
lected in the prone position after luciferin injection with the Xenogen IVIS Lumina Imaging System (Caliper Life 
Sciences, Cheshire, UK), and photons emitted from the flanks were quantified by using Xenogen Living Image 
Software (Caliper Life Science).
Histopathologic and immunohistochemical analysis. Tumors were fixed in 10% neutralized forma-
lin and embedded in paraffin blocks. Paraffin-embedded sections (4 μ m) were prepared for hematoxylin/eosin 
(H&E) staining and immunohistochemical examination. Immunostaining with rabbit anti-Ki67 mAb (Abcam, 
Cambridge, MA, USA) using standard techniques was used to detect proliferating tumor cells within tumor 
tissues. The photographs of immunostained sections were obtained by light microscopy. The number of immu-
noreactive cells for Ki67 was calculated in five randomly selected fields in each tumor by using ImageJ software.
Statistical analysis. Data are expressed as means ± SD. Determination of significant differences was 
assessed using the Student’s t-test. P values less than 0.05 were considered to indicate statistical significance.
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